AIM ImmunoTech Inc. (AIM)
USD 0.13
(-0.79%)
USD 0.13
(-0.79%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -28.96 Million USD | -37.35% |
| 2022 | -21.08 Million USD | 1.98% |
| 2021 | -21.51 Million USD | -32.32% |
| 2020 | -16.25 Million USD | -50.18% |
| 2019 | -10.82 Million USD | -10.32% |
| 2018 | -9.81 Million USD | -18.82% |
| 2017 | -8.25 Million USD | -10.09% |
| 2016 | -7.5 Million USD | 50.74% |
| 2015 | -15.23 Million USD | 12.72% |
| 2014 | -17.45 Million USD | -7.55% |
| 2013 | -16.22 Million USD | 6.51% |
| 2012 | -17.35 Million USD | -92.5% |
| 2011 | -9.01 Million USD | 31.37% |
| 2010 | -13.13 Million USD | 2.25% |
| 2009 | -13.43 Million USD | -9.98% |
| 2008 | -12.21 Million USD | 32.64% |
| 2007 | -18.13 Million USD | 6.5% |
| 2006 | -19.39 Million USD | -46.82% |
| 2005 | -13.21 Million USD | 45.27% |
| 2004 | -24.14 Million USD | -63.44% |
| 2003 | -14.77 Million USD | -98.95% |
| 2002 | -7.42 Million USD | 18.26% |
| 2001 | -9.08 Million USD | -6.21% |
| 2000 | -8.55 Million USD | 7.04% |
| 1999 | -9.2 Million USD | -26.03% |
| 1998 | -7.3 Million USD | -19.67% |
| 1997 | -6.1 Million USD | -32.61% |
| 1996 | -4.6 Million USD | -155.56% |
| 1995 | -1.8 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -5.81 Million USD | 53.75% |
| 2024 Q2 | -1.83 Million USD | 68.44% |
| 2023 Q4 | -12.57 Million USD | -60.9% |
| 2023 Q2 | -4.9 Million USD | -72.43% |
| 2023 Q3 | -7.81 Million USD | -59.22% |
| 2023 Q1 | -2.84 Million USD | 33.73% |
| 2023 FY | -28.96 Million USD | -37.35% |
| 2022 Q1 | -4.48 Million USD | 23.23% |
| 2022 FY | -21.08 Million USD | 1.98% |
| 2022 Q4 | -4.29 Million USD | 31.25% |
| 2022 Q3 | -6.24 Million USD | -24.81% |
| 2022 Q2 | -5 Million USD | -11.56% |
| 2021 Q3 | -3.82 Million USD | 34.89% |
| 2021 FY | -21.51 Million USD | -32.32% |
| 2021 Q4 | -5.84 Million USD | -52.8% |
| 2021 Q1 | -3.57 Million USD | 9.02% |
| 2021 Q2 | -5.87 Million USD | -64.18% |
| 2020 Q2 | -3.37 Million USD | 11.5% |
| 2020 Q4 | -3.93 Million USD | -19.0% |
| 2020 Q3 | -3.3 Million USD | 1.9% |
| 2020 FY | -16.25 Million USD | -50.18% |
| 2020 Q1 | -3.8 Million USD | -220.54% |
| 2019 Q2 | -2.02 Million USD | 39.76% |
| 2019 Q3 | -2.94 Million USD | -45.29% |
| 2019 FY | -10.82 Million USD | -10.32% |
| 2019 Q4 | -1.18 Million USD | 59.7% |
| 2019 Q1 | -3.36 Million USD | -109.58% |
| 2018 Q3 | -3.07 Million USD | -27.45% |
| 2018 Q1 | -2.71 Million USD | -36.13% |
| 2018 Q4 | -1.6 Million USD | 47.79% |
| 2018 FY | -9.81 Million USD | -18.82% |
| 2018 Q2 | -2.41 Million USD | 10.98% |
| 2017 Q2 | -2.19 Million USD | 22.26% |
| 2017 Q4 | -1.99 Million USD | -59.19% |
| 2017 Q1 | -2.82 Million USD | -140.49% |
| 2017 FY | -8.25 Million USD | -10.09% |
| 2017 Q3 | -1.25 Million USD | 42.91% |
| 2016 FY | -7.5 Million USD | 50.74% |
| 2016 Q1 | -2.16 Million USD | 31.02% |
| 2016 Q2 | -1.3 Million USD | 39.79% |
| 2016 Q3 | -2.86 Million USD | -119.65% |
| 2016 Q4 | -1.17 Million USD | 59.01% |
| 2015 Q3 | -3.8 Million USD | 21.51% |
| 2015 Q1 | -3.44 Million USD | 22.69% |
| 2015 Q4 | -3.13 Million USD | 17.51% |
| 2015 Q2 | -4.84 Million USD | -40.64% |
| 2015 FY | -15.23 Million USD | 12.72% |
| 2014 Q1 | -3.83 Million USD | -20.06% |
| 2014 Q4 | -4.45 Million USD | -6.04% |
| 2014 FY | -17.45 Million USD | -7.55% |
| 2014 Q2 | -4.95 Million USD | -29.2% |
| 2014 Q3 | -4.2 Million USD | 15.21% |
| 2013 Q1 | -3.61 Million USD | 33.85% |
| 2013 Q4 | -3.19 Million USD | 37.79% |
| 2013 FY | -16.22 Million USD | 6.51% |
| 2013 Q3 | -5.13 Million USD | -19.92% |
| 2013 Q2 | -4.28 Million USD | -18.61% |
| 2012 Q3 | -6.58 Million USD | -119.57% |
| 2012 Q2 | -3 Million USD | -29.98% |
| 2012 Q1 | -2.3 Million USD | 25.91% |
| 2012 Q4 | -5.45 Million USD | 17.12% |
| 2012 FY | -17.35 Million USD | -92.5% |
| 2011 Q3 | -2.74 Million USD | -19.44% |
| 2011 Q2 | -2.29 Million USD | -164.9% |
| 2011 Q1 | -866 Thousand USD | 59.94% |
| 2011 FY | -9.01 Million USD | 31.37% |
| 2011 Q4 | -3.11 Million USD | -13.69% |
| 2010 Q2 | -3.67 Million USD | 9.1% |
| 2010 Q3 | -3.25 Million USD | 11.48% |
| 2010 Q4 | -2.16 Million USD | 33.56% |
| 2010 Q1 | -4.04 Million USD | 0.05% |
| 2010 FY | -13.13 Million USD | 2.25% |
| 2009 Q4 | -4.04 Million USD | -66.16% |
| 2009 FY | -13.43 Million USD | -9.98% |
| 2009 Q1 | -3.08 Million USD | -8.81% |
| 2009 Q2 | -3.87 Million USD | -25.36% |
| 2009 Q3 | -2.43 Million USD | 37.08% |
| 2008 FY | -12.21 Million USD | 32.64% |
| 2008 Q4 | -2.83 Million USD | 16.93% |
| 2008 Q3 | -3.41 Million USD | -21.88% |
| 2008 Q1 | -3.16 Million USD | 6.8% |
| 2008 Q2 | -2.8 Million USD | 11.47% |
| 2007 Q2 | -3.92 Million USD | 23.04% |
| 2007 Q3 | -5.71 Million USD | -45.68% |
| 2007 Q1 | -5.1 Million USD | -11.06% |
| 2007 Q4 | -3.39 Million USD | 40.61% |
| 2007 FY | -18.13 Million USD | 6.5% |
| 2006 Q3 | -3.8 Million USD | 25.07% |
| 2006 FY | -19.39 Million USD | -46.82% |
| 2006 Q2 | -5.08 Million USD | 14.17% |
| 2006 Q4 | -4.59 Million USD | -20.62% |
| 2006 Q1 | -5.92 Million USD | -71.35% |
| 2005 Q1 | -3.05 Million USD | 2.58% |
| 2005 Q4 | -3.45 Million USD | -19.67% |
| 2005 FY | -13.21 Million USD | 45.27% |
| 2005 Q2 | -3.81 Million USD | -24.91% |
| 2005 Q3 | -2.88 Million USD | 24.34% |
| 2004 FY | -24.14 Million USD | -63.44% |
| 2004 Q1 | -8.04 Million USD | -98.96% |
| 2004 Q2 | -5.95 Million USD | 25.94% |
| 2004 Q3 | -7 Million USD | -17.65% |
| 2004 Q4 | -3.13 Million USD | 55.24% |
| 2003 FY | -14.77 Million USD | -98.95% |
| 2003 Q4 | -4.04 Million USD | 25.45% |
| 2003 Q3 | -5.42 Million USD | -46.98% |
| 2003 Q1 | -1.61 Million USD | -14.6% |
| 2003 Q2 | -3.68 Million USD | -128.14% |
| 2002 Q1 | -1.48 Million USD | 29.65% |
| 2002 Q4 | -1.41 Million USD | 25.38% |
| 2002 Q3 | -1.89 Million USD | 28.21% |
| 2002 Q2 | -2.63 Million USD | -77.02% |
| 2002 FY | -7.42 Million USD | 18.26% |
| 2001 Q2 | -2.34 Million USD | 5.52% |
| 2001 Q3 | -2.14 Million USD | 8.45% |
| 2001 Q4 | -2.11 Million USD | 1.4% |
| 2001 FY | -9.08 Million USD | -6.21% |
| 2001 Q1 | -2.48 Million USD | -1.05% |
| 2000 Q3 | -2.06 Million USD | -0.29% |
| 2000 FY | -8.55 Million USD | 7.04% |
| 2000 Q2 | -2.05 Million USD | -4.45% |
| 2000 Q1 | -1.97 Million USD | -3.79% |
| 2000 Q4 | -2.45 Million USD | -18.81% |
| 1999 FY | -9.2 Million USD | -26.03% |
| 1999 Q4 | -1.9 Million USD | 0.0% |
| 1999 Q3 | -1.9 Million USD | 26.92% |
| 1999 Q2 | -2.6 Million USD | 10.34% |
| 1999 Q1 | -2.9 Million USD | -16.0% |
| 1998 Q1 | -1.5 Million USD | -25.0% |
| 1998 Q2 | -1.6 Million USD | -6.67% |
| 1998 Q3 | -1.7 Million USD | -6.25% |
| 1998 FY | -7.3 Million USD | -19.67% |
| 1998 Q4 | -2.5 Million USD | -47.06% |
| 1997 Q2 | -1.1 Million USD | 52.17% |
| 1997 Q3 | -1.5 Million USD | -36.36% |
| 1997 FY | -6.1 Million USD | -32.61% |
| 1997 Q4 | -1.2 Million USD | 20.0% |
| 1997 Q1 | -2.3 Million USD | -76.92% |
| 1996 Q1 | -700 Thousand USD | -133.33% |
| 1996 Q4 | -1.3 Million USD | 13.33% |
| 1996 FY | -4.6 Million USD | -155.56% |
| 1996 Q3 | -1.5 Million USD | -36.36% |
| 1996 Q2 | -1.1 Million USD | -57.14% |
| 1995 Q4 | -300 Thousand USD | 40.0% |
| 1995 Q3 | -500 Thousand USD | 0.0% |
| 1995 Q1 | -500 Thousand USD | 0.0% |
| 1995 Q2 | -500 Thousand USD | 0.0% |
| 1995 FY | -1.8 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -235.519% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 58.053% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 40.674% |
| Azitra, Inc. | -11.28 Million USD | -156.669% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -279.382% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -292.397% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 0.869% |
| CEL-SCI Corporation | -32.36 Million USD | 10.517% |
| iBio, Inc. | -24.9 Million USD | -16.281% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | -34.795% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | -46.473% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | -26.24% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -90.826% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -200.436% |
| NanoViricides, Inc. | -8.29 Million USD | -249.186% |
| Oragenics, Inc. | -20.65 Million USD | -40.213% |
| BiomX Inc. | -26.16 Million USD | -10.673% |
| BiomX Inc. | -26.16 Million USD | -10.673% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 448.436% |
| Palatin Technologies, Inc. | -29.73 Million USD | 2.603% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 35.949% |